Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus)
Identifieur interne : 005921 ( Main/Exploration ); précédent : 005920; suivant : 005922Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus)
Auteurs : R. K. B. Pearce ; M. Jackson ; L. Smith ; Jenner ; C. D. Marsden [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 1995-11.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Singe.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine, Administration, Oral, Animal, Animal model, Animals, Antiparkinson Agents (toxicity), Callithrix, Carbidopa (toxicity), Disease Models, Animal, Dopa, Dopamine Agonists (toxicity), Dopamine agonists, Dose-Response Relationship, Drug, Drug Synergism, Dyskinesia, Dyskinesia, Drug-Induced (physiopathology), Dyskinesias, Female, Levodopa (toxicity), L‐DOPA, Male, Marmosets, Monkey, Neurologic Examination (drug effects), Parkinson Disease, Secondary (chemically induced), Parkinson's disease, Toxicity.
- MESH :
- chemical , toxicity : Antiparkinson Agents, Carbidopa, Dopamine Agonists, Levodopa.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Neurologic Examination.
- physiopathology : Dyskinesia, Drug-Induced.
- Administration, Oral, Animals, Callithrix, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Synergism, Female, Male.
Abstract
Dyskinesias occur in the majority of patients with Parkinson's disease chronically treated with L‐DOPA and also occur in several nonhuman primate species after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) and L‐DOPA treatment. The common marmoset (Callithrix jacchus) shows parkinsonian motor deficits after MPTP administration, and we now report dyskinesias occurring in this species during chronic L‐DOPA exposure. Marmosets rendered chronically parkinsonian after MPTP administration were treated orally with L‐DOPA plus carbidopa for 3 weeks. After several days the animals began to display chorea, choreoathetosis, and dystonia. The severity of dyskinesias varied between the animals, with the most severely parkinsonian animals displaying the most dyskinetic movements. Each animal showed an idiosyncratic pattern of dyskinesias, which was highly reproducible. These L‐DOPA‐primed animals also received other D2, D1, and agonist drugs. Quinpirole, bromocriptine, pergolide, apomorphine, and A‐77636 all produced dyskinesias that were identical in character to those seen after L‐DOPA administration, but the D1 agonist A‐77636 gradually abolished dyskinesias while preserving its antiparkinsonian activity. The MPTP‐treated marmoset provides a useful model in which to study dyskinesias in Parkinson's disease and to examine new therapeutic strategies aimed at alleviating this common side effect of chronic dopamine replacement therapy.
Url:
DOI: 10.1002/mds.870100606
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000753
- to stream Istex, to step Curation: 000753
- to stream Istex, to step Checkpoint: 003D52
- to stream PubMed, to step Corpus: 004910
- to stream PubMed, to step Curation: 004910
- to stream PubMed, to step Checkpoint: 004999
- to stream Ncbi, to step Merge: 004B19
- to stream Ncbi, to step Curation: 004B19
- to stream Ncbi, to step Checkpoint: 004B19
- to stream Main, to step Merge: 008A83
- to stream PascalFrancis, to step Corpus: 003437
- to stream PascalFrancis, to step Curation: 003387
- to stream PascalFrancis, to step Checkpoint: 003512
- to stream Main, to step Merge: 008C09
- to stream Main, to step Curation: 005921
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus)</title><author><name sortKey="Pearce, R K B" sort="Pearce, R K B" uniqKey="Pearce R" first="R. K. B." last="Pearce">R. K. B. Pearce</name></author><author><name sortKey="Jackson, M" sort="Jackson, M" uniqKey="Jackson M" first="M." last="Jackson">M. Jackson</name></author><author><name sortKey="Smith, L" sort="Smith, L" uniqKey="Smith L" first="L." last="Smith">L. Smith</name></author><author><name sortKey="Jenner" sort="Jenner" uniqKey="Jenner" last="Jenner">Jenner</name></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:38DE195CF3AB20E72E30584A1C86EB0B32005852</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1002/mds.870100606</idno><idno type="url">https://api.istex.fr/document/38DE195CF3AB20E72E30584A1C86EB0B32005852/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000753</idno><idno type="wicri:Area/Istex/Curation">000753</idno><idno type="wicri:Area/Istex/Checkpoint">003D52</idno><idno type="wicri:doubleKey">0885-3185:1995:Pearce R:chronic:l:dopa</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8749992</idno><idno type="wicri:Area/PubMed/Corpus">004910</idno><idno type="wicri:Area/PubMed/Curation">004910</idno><idno type="wicri:Area/PubMed/Checkpoint">004999</idno><idno type="wicri:Area/Ncbi/Merge">004B19</idno><idno type="wicri:Area/Ncbi/Curation">004B19</idno><idno type="wicri:Area/Ncbi/Checkpoint">004B19</idno><idno type="wicri:doubleKey">0885-3185:1995:Pearce R:chronic:l:dopa</idno><idno type="wicri:Area/Main/Merge">008A83</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:96-0080253</idno><idno type="wicri:Area/PascalFrancis/Corpus">003437</idno><idno type="wicri:Area/PascalFrancis/Curation">003387</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003512</idno><idno type="wicri:doubleKey">0885-3185:1995:Pearce R:chronic:l:dopa</idno><idno type="wicri:Area/Main/Merge">008C09</idno><idno type="wicri:Area/Main/Curation">005921</idno><idno type="wicri:Area/Main/Exploration">005921</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus)</title><author><name sortKey="Pearce, R K B" sort="Pearce, R K B" uniqKey="Pearce R" first="R. K. B." last="Pearce">R. K. B. Pearce</name><affiliation><wicri:noCountry code="subField">King's College London</wicri:noCountry></affiliation></author><author><name sortKey="Jackson, M" sort="Jackson, M" uniqKey="Jackson M" first="M." last="Jackson">M. Jackson</name><affiliation><wicri:noCountry code="subField">King's College London</wicri:noCountry></affiliation></author><author><name sortKey="Smith, L" sort="Smith, L" uniqKey="Smith L" first="L." last="Smith">L. Smith</name><affiliation><wicri:noCountry code="subField">King's College London</wicri:noCountry></affiliation></author><author><name sortKey="Jenner" sort="Jenner" uniqKey="Jenner" last="Jenner">Jenner</name><affiliation><wicri:noCountry code="subField">King's College London</wicri:noCountry></affiliation></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>University Department of Clinical Neurology, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1995-11">1995-11</date><biblScope unit="vol">10</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="731">731</biblScope><biblScope unit="page" to="740">740</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">38DE195CF3AB20E72E30584A1C86EB0B32005852</idno><idno type="DOI">10.1002/mds.870100606</idno><idno type="ArticleID">MDS870100606</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine</term><term>Administration, Oral</term><term>Animal</term><term>Animal model</term><term>Animals</term><term>Antiparkinson Agents (toxicity)</term><term>Callithrix</term><term>Carbidopa (toxicity)</term><term>Disease Models, Animal</term><term>Dopa</term><term>Dopamine Agonists (toxicity)</term><term>Dopamine agonists</term><term>Dose-Response Relationship, Drug</term><term>Drug Synergism</term><term>Dyskinesia</term><term>Dyskinesia, Drug-Induced (physiopathology)</term><term>Dyskinesias</term><term>Female</term><term>Levodopa (toxicity)</term><term>L‐DOPA</term><term>Male</term><term>Marmosets</term><term>Monkey</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson's disease</term><term>Toxicity</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Animals</term><term>Callithrix</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Drug Synergism</term><term>Female</term><term>Male</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animal</term><term>Dopa</term><term>Dyskinésie</term><term>Modèle animal</term><term>Singe</term><term>Toxicité</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dyskinesias occur in the majority of patients with Parkinson's disease chronically treated with L‐DOPA and also occur in several nonhuman primate species after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) and L‐DOPA treatment. The common marmoset (Callithrix jacchus) shows parkinsonian motor deficits after MPTP administration, and we now report dyskinesias occurring in this species during chronic L‐DOPA exposure. Marmosets rendered chronically parkinsonian after MPTP administration were treated orally with L‐DOPA plus carbidopa for 3 weeks. After several days the animals began to display chorea, choreoathetosis, and dystonia. The severity of dyskinesias varied between the animals, with the most severely parkinsonian animals displaying the most dyskinetic movements. Each animal showed an idiosyncratic pattern of dyskinesias, which was highly reproducible. These L‐DOPA‐primed animals also received other D2, D1, and agonist drugs. Quinpirole, bromocriptine, pergolide, apomorphine, and A‐77636 all produced dyskinesias that were identical in character to those seen after L‐DOPA administration, but the D1 agonist A‐77636 gradually abolished dyskinesias while preserving its antiparkinsonian activity. The MPTP‐treated marmoset provides a useful model in which to study dyskinesias in Parkinson's disease and to examine new therapeutic strategies aimed at alleviating this common side effect of chronic dopamine replacement therapy.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li></region></list><tree><noCountry><name sortKey="Jackson, M" sort="Jackson, M" uniqKey="Jackson M" first="M." last="Jackson">M. Jackson</name><name sortKey="Jenner" sort="Jenner" uniqKey="Jenner" last="Jenner">Jenner</name><name sortKey="Pearce, R K B" sort="Pearce, R K B" uniqKey="Pearce R" first="R. K. B." last="Pearce">R. K. B. Pearce</name><name sortKey="Smith, L" sort="Smith, L" uniqKey="Smith L" first="L." last="Smith">L. Smith</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005921 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005921 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:38DE195CF3AB20E72E30584A1C86EB0B32005852
|texte= Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus)
}}
| This area was generated with Dilib version V0.6.23. |  |